San Diego Biotech Iambic Therapeutics Filed for IPO

The company seeks to raise $135 million through an offering of 9.4 million shares.

Updated on Oct. 9, 2026 in Biotech

San Diego Biotech Iambic Therapeutics Filed for IPO

Live Poll

Is now a good time for individual investors to buy into new biotech company stock offerings?

San Diego-based Iambic Therapeutics has filed for an initial public offering to raise $135 million. The biotech firm is offering 9.4 million shares at a price range between $15 and $17 each.

Why it matters

The company intends to use the capital from this offering to support clinical development of its pipeline drugs and its proprietary molecular superintelligence platform. This funding is expected to support operations through the end of 2028.

The firm operates with 171 full-time employees and maintains a cash balance of $207.9 million. It plans to issue 9.4 million shares with an option for underwriters to purchase an additional 1.4 million shares.

The players

Iambic Therapeutics

This San Diego-based biotechnology company focuses on developing new medical treatments using a molecular superintelligence platform.

The details

Founded in 2019, Iambic Therapeutics has previously completed three significant funding rounds, including a $53 million Series A in 2021 and a $100 million Series B in 2023. The new offering is expected to generate $150 million in gross proceeds, with net proceeds potentially reaching $155.9 million if full share options are exercised.

Iambic Therapeutics was established in 2019.
A $53 million Series A funding round took place in 2021.
The firm completed a $100 million Series B round in 2023.
A third funding round was held in November 2025.
The company reported $207.9 million in cash reserves as of June 2026.

The Tech Race

This transition to the public markets marks a significant evolution for the company as it moves from venture-backed research to public-facing drug development. The move highlights the broader competition for capital among biotech firms leveraging proprietary AI and superintelligence tools.

This IPO is a corporate milestone that provides the capital necessary for the company to continue its research and development programs. Prospective retail investors should monitor the final pricing and debut date of the shares as the company moves through the regulatory process.

The takeaway

Public offerings are a critical step for biotech companies seeking the runway required to advance drug pipelines through lengthy clinical trial phases. Investors tracking these moves gain insight into which AI-driven research models are attracting significant institutional interest.